The FDA Drugs@FDA record shows a supplement dated 23 October on BLA 761362, Jubbonti (denosumab-bbdz), held by Sandoz. The suffix marks it as a biosimilar of denosumab, used for osteoporosis.
The record does not say what the supplement covers — labelling, manufacturing or another change — so its clinical significance cannot be judged from this entry.
For older patients on any denosumab product, the practical point is unchanged: it should not be stopped without a plan for follow-on treatment, because bone loss and vertebral fractures can rebound after discontinuation. Whether this product is available in India is not stated in the record.
- An FDA supplement for denosumab-bbdz (Jubbonti) is listed on 23 October.
- The record does not state what the supplement changes.
- Do not stop any denosumab product without a follow-on plan.
- Check the current label before assuming any change in indication.
Why it matters
Biosimilar denosumab widens access, which makes planned continuation in frail patients even more important.
Don't overread it
A supplement listing without detail is not evidence of a new indication or safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for geriatrics, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free